SGLT2 inhibitors in T2D and associated comorbidities - differentiating within the class
For patients with type 2 diabetes (T2D), cardiovascular disease (CVD) is the single most common cause of mortality. In 2008 and 2012, the Federal Drug Administration (FDA) and the European Medicines Agency (EMA) respectively mandated cardiovascular outcomes trials (CVOTs) on all new anti-diabetic ag...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2019
|
| Sorozat: | BMC ENDOCRINE DISORDERS
19 |
| doi: | 10.1186/s12902-019-0387-y |
| mtmt: | 30744468 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/16406 |